ArticleClinical physiology and functional imaging2026
Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work.
Article in Clinical physiology and functional imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the effect of 12-week Mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy (oHCM) using myocardial work analysis, and explore its role in myocardial energy metabolism.
methodsThirty-five oHCM patients and 35 matched healthy controls were enroled. Patients received Mavacamten for 12 weeks. At baseline and post-treatment, we measured LVOT gradient, LVEF, GLS, myocardial work parameters [GWI, GCW, GWW, GWE], mitral regurgitation severity, and SAM.
resultsMyocardial work parameters showed good reproducibility (ICCs > 0.75). After 12 weeks, resting and provoked LVOT gradients significantly decreased (both p < 0.001). Proportions of moderate/severe mitral regurgitation and SAM reduced. GWI, GCW, and GWW decreased (p < 0.001), while GWE increased (p < 0.001). NT-proBNP decreased and NYHA functional class improved (p < 0.001). LVEF, GLS, and left atrial diameter showed no significant changes. Compared with controls, baseline oHCM patients had lower GWI, GCW, GWE and higher GWW (all p < 0.001). After treatment, GWE remained lower than controls (p < 0.001), and GWW remained higher (p < 0.001).
conclusionTwelve-week Mavacamten reduces LVOT obstruction in oHCM, accompanied by decreased GWI and increased GWE, while preserving systolic function and improving symptoms. Myocardial work parameters may serve as novel non-invasive references for treatment evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.